Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 272 results

NHS v Servier: unlawful means tort claim fails, but the long-running saga continues

UK17-08-2021Beatriz San Martin and Shishu Chen

The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

EU10-08-2021Sophie Topham

In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.

UK experimental use exemptions: part 1—the original

15-07-2021Sophie Topham

In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

EPO’s new examination guidelines: what you need to know

EU06-04-2021Clare Roskell and Samantha Moodie

The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

Second medical use: a regulatory perspective

UK08-02-2021Jackie Mulryne

Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.

The plausibility battleground at the EPO

EU09-11-2020Markus Grammel

Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

A stricter interpretation: the EPO and antibodies

EU27-10-2020Joachim Wachenfeld and Florian Grasser

Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

Why Santen ends Neurim-style SPCs

EU25-08-2020Robert Stephen and Gareth Morgan

In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.

How patents for transgenic mice got caught in a sufficiency trap

16-07-2020David Fyfield

As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.

EPO’s G3/19: no turning back?

Germany02-07-2020Anna Gregson

The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.

Showing 1 to 10 of 272 results

LSIPR